Cargando…

Hormonal Male Contraception: Getting to Market

Rates of unplanned pregnancies are high and stagnant globally, burdening women, families and the environment. Local limitations placed upon contraceptive access and abortion services exacerbate global disparities for women. Despite survey data suggesting men and their partners are eager for expanded...

Descripción completa

Detalles Bibliográficos
Autores principales: Page, Stephanie T., Blithe, Diana, Wang, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203677/
https://www.ncbi.nlm.nih.gov/pubmed/35721718
http://dx.doi.org/10.3389/fendo.2022.891589
_version_ 1784728748594036736
author Page, Stephanie T.
Blithe, Diana
Wang, Christina
author_facet Page, Stephanie T.
Blithe, Diana
Wang, Christina
author_sort Page, Stephanie T.
collection PubMed
description Rates of unplanned pregnancies are high and stagnant globally, burdening women, families and the environment. Local limitations placed upon contraceptive access and abortion services exacerbate global disparities for women. Despite survey data suggesting men and their partners are eager for expanded male contraceptive options, efforts to develop such agents have been stymied by a paucity of monetary investment. Modern male hormonal contraception, like female hormonal methods, relies upon exogenous progestins to suppress the hypothalamic-pituitary-gonadal axis, in turn suppressing testicular testosterone production and sperm maturation. Addition of an androgen augments gonadotropin suppression, more effectively suppressing spermatogenesis in men, and provides androgenic support for male physiology. Previous contraceptive efficacy studies in couples have shown that hormonal male methods are effective and reversible. Recent efforts have been directed at addressing potential user and regulatory concerns by utilizing novel steroids and varied routes of hormone delivery. Provision of effective contraceptive options for men and women is an urgent public health need. Recognizing and addressing the gaps in our contraceptive options and engaging men in family planning will help reduce rates of unplanned pregnancies in the coming decades.
format Online
Article
Text
id pubmed-9203677
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92036772022-06-18 Hormonal Male Contraception: Getting to Market Page, Stephanie T. Blithe, Diana Wang, Christina Front Endocrinol (Lausanne) Endocrinology Rates of unplanned pregnancies are high and stagnant globally, burdening women, families and the environment. Local limitations placed upon contraceptive access and abortion services exacerbate global disparities for women. Despite survey data suggesting men and their partners are eager for expanded male contraceptive options, efforts to develop such agents have been stymied by a paucity of monetary investment. Modern male hormonal contraception, like female hormonal methods, relies upon exogenous progestins to suppress the hypothalamic-pituitary-gonadal axis, in turn suppressing testicular testosterone production and sperm maturation. Addition of an androgen augments gonadotropin suppression, more effectively suppressing spermatogenesis in men, and provides androgenic support for male physiology. Previous contraceptive efficacy studies in couples have shown that hormonal male methods are effective and reversible. Recent efforts have been directed at addressing potential user and regulatory concerns by utilizing novel steroids and varied routes of hormone delivery. Provision of effective contraceptive options for men and women is an urgent public health need. Recognizing and addressing the gaps in our contraceptive options and engaging men in family planning will help reduce rates of unplanned pregnancies in the coming decades. Frontiers Media S.A. 2022-06-03 /pmc/articles/PMC9203677/ /pubmed/35721718 http://dx.doi.org/10.3389/fendo.2022.891589 Text en Copyright © 2022 Page, Blithe and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Page, Stephanie T.
Blithe, Diana
Wang, Christina
Hormonal Male Contraception: Getting to Market
title Hormonal Male Contraception: Getting to Market
title_full Hormonal Male Contraception: Getting to Market
title_fullStr Hormonal Male Contraception: Getting to Market
title_full_unstemmed Hormonal Male Contraception: Getting to Market
title_short Hormonal Male Contraception: Getting to Market
title_sort hormonal male contraception: getting to market
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203677/
https://www.ncbi.nlm.nih.gov/pubmed/35721718
http://dx.doi.org/10.3389/fendo.2022.891589
work_keys_str_mv AT pagestephaniet hormonalmalecontraceptiongettingtomarket
AT blithediana hormonalmalecontraceptiongettingtomarket
AT wangchristina hormonalmalecontraceptiongettingtomarket